The Analysis of the FIX‐inhibitor Risks Associated With the F9 Genotype in Patients With Haemophilia B Exposes the Involvement of Nonsense Mediated‐Decay: Argentinean and International Series
Haemophilia · 2026-11 · 32 (6) · 1488-1497
DOI: 10.1111/hae.70356 ↗Abstract
ABSTRACT Introduction Haemophilia B (HB) associates with deleterious variants in F9 . HB management with FIX‐concentrate infusions may be ineffective in 3%–9% patients who develop FIX‐inhibitors. Aim To present our HB‐series ( n = 136) including all Argentinean patients with FIX‐inhibitors ( n = 13). To estimate F9 ‐genotype‐associated FIX‐inhibitor risks from our series (GMH), and HB‐international databases, FIX‐UCL and EAHAD. Methods F9 ‐genotyping was performed by conventional protocols; or by short‐read‐NGS on a new F9 ‐panel. FIX‐inhibitor risks were estimated by case(inh+)/control(inh‐) studies using OR(95%CI). Results The spectrum of F9 ‐genotypes from our GMH‐series resulted similar to the one compiled in international databases, prevailing missense (45%), and nonsense (21%) in severe‐HB and missense defects (> 80%) in non‐severe‐HB. Our set of HB‐patients with FIX‐inhibitors mostly included large‐deletions and nonsense mutations, and 38.5% developed allergic reactions. Case/Control studies mainly aligned FIX‐inhibitor risks in all three datasets. Considering severe‐HB in GMH( n = 91)//FIX‐UCL( n = 349)//EAHAD( n = 590), we observed a high‐risk group that comprised entire‐ F9 ‐deletions with highly‐significant ORs of 24//12//35, all‐large‐deletions, 7//7//17 and nonsense mutations, 3//3//2; and a low‐risk group confined to missense F9 ‐variants with highly‐significant protective ORs, 0.04//0.11//0.03, whilst other F9 ‐variants did not differ from the null‐hypothesis. Equal analysis from all‐severities HB patients closely agreed with these results. An analysis of NS and FIX‐inhibitor risks suggested the involvement of nonsense‐mediated decay (NMD) in F9 : nonsense ( F9 ‐exons_1–7) vs nonsense ( F9 ‐exon_8) resulted in highly‐significantly incremented risks in both FIX‐UCL( n = 124)//EAHAD( n = 171), ORs of 4(2–9)//4(3–6). Conclusion Our study provides robust estimations of F9 ‐genotype‐associated FIX‐inhibitor risks in HB‐patients and exposed the involvement of NMD.
EUVIMED